The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of TQB3454 Tablets in Patients With Blood Tumors
Official Title: A Phase Ib Clinical Trial of TQB3454 Tablets in Patients With Blood Tumors
Study ID: NCT06218771
Brief Summary: The purpose of this clinical trial is to evaluate the safety of TQB3454 tablets in patients with acute myeloid leukemia and myelodysplastic syndrome, and determine the phase II recommended dose.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Cangzhou people's Hospital, Cangzhou, Hebei, China
The Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Wuxi People's Hospital, Wuxi, Jiangsu, China
Affiliated Hospital of Binzhou Medical College, Binzhou, Shandong, China
Yantai Mountain Hospital, Yantai, Shandong, China
Yantai Yuhuangding Hospital, Yantai, Shandong, China
Shanghai Tongren Hospital, Shanghai, Shanghai, China
Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China